Edgewise Therapeutics, Inc. (EWTX) NASDAQ

16.19

+0.44(+2.79%)

Updated at September 30 01:35PM

Currency In USD

Edgewise Therapeutics, Inc.

Address

3415 Colorado Avenue

Boulder, CO 80303

United States of America

Phone

303 735 8373

Sector

Healthcare

Industry

Biotechnology

Employees

117

First IPO Date

March 26, 2021

Key Executives

NameTitlePayYear Born
Dr. Kevin Koch Ph.D.President, Chief Executive Officer & Director1.07M1960
Mr. R. Michael CarruthersChief Financial Officer386,0091958
Dr. Alan J. Russell Ph.D.Co-Founder, Chief Scientific Officer & Director657,5201970
Dr. Behrad Derakhshan Ph.D.Chief Operating Officer796,5361980
Dr. Joanne M. Donovan M.D., Ph.D.Chief Medical Officer824,8171957
Dr. Robert Blaustein M.D., Ph.D.Chief Development Officer01961
Mr. John R. Moore J.D.General Counsel01964

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.